drugset / Trial / NCT02838797
RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease
Phase 1
Completed
51 enrolled
Virginia Commonwealth University
Michael J. Fox Foundation for Parkinson's Research · collabRaQualia Pharma Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a study to determine the safety and tolerability of a new medicine (RQ10) for gastrointestinal symptoms in Parkinson's disease. The investigators will also begin to look at the effect of this medicine on gastrointestinal problems. The results will determine if future studies are appropriate. In this study, RQ10 will be compared to a placebo (a look-alike inactive substance). Participation will include multiple office visits. Approximately 48 people will participate.
Timeline
- Start
- 2016-06
- Primary completion
- 2019-08-20
- Completion
- 2019-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RQ-00000010 | Unknown | 2 ug | Oral |
| Subject | RQ-00000010 | Unknown | 10 ug | Oral |
| Subject | RQ-00000010 | Unknown | 50 ug | Oral |
| Subject | RQ-00000010 | Unknown | 100 ug | Oral |
| Subject | RQ-00000010 | Unknown | 200 ug | Oral |